travelerkasce.blogg.se

A randomized phase 2b study of ABT-494, a selective JAK1 inhibitor in patients with rheumatoid arthritis and an inadequate response to methotrexate. A phase 2b study of ABT-494, a selective JAK1 inhibitor, in patients with rheumatoid arthritis and an inadequate response to anti–TNF therapy. Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study. A double-blind, placebo-controlled, twelve-week, dose-ranging study of decernotinib, an oral selective JAK-3 inhibitor, as monotherapy in patients with active rheumatoid arthritis. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Characterization of changes in lymphocyte subsets in baricitinib-treated patients with rheumatoid arthritis in two phase 3 studies. Characterisation of changes in lymphocyte subsets in baricitinib-treated patients with rheumatoid arthritis in a phase 3 study (RA-BEAM).

Safety profile of baricitinib in patients with active RA: an integrated analysis. Baricitinib, an oral Janus kinase (JAK)1/JAK2 inhibitor, in patients with active rheumatoid arthritis (RA) and an inadequate response to TNF inhibitors: results of the phase 3 RA-Beacon study. Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial. Relationship between NK cell count and important safety events in rheumatoid arthritis patients treated with tofacitinib. Tofacitinib, an oral JAK inhibitor, in the treatment of rheumatoid arthritis: safety and clinical and radiographic efficacy in open-label, long-term extension studies over 7 years. Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure. Identification of a potent Janus kinase 3 inhibitor with high selectivity within the Janus kinase family. Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. Functional correlations of pathogenesis-driven gene expression signatures in tuberculosis.

JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Cytokine signaling modules in inflammatory responses.

Jak–STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Back to the future: oral targeted therapy for RA and other autoimmune diseases. A new modality for immunosuppression: targeting the JAK/STAT pathway.